MediWound Ltd.
MDWD · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 26.50M | 13.17M | -7.66M | -19.60M | -3.93 |
| 2023 FY | 18.69M | 3.58M | -15.50M | -6.72M | -0.75 |
| 2024 FY | 20.22M | 2.63M | -19.38M | -30.22M | -3.03 |
| 2025 FY | 16.96M | 3.25M | -25.28M | -23.88M | -2.10 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 50.02M | 39.10M | 33.90M | 846.00K | 10.91M |
| 2023 FY | 66.46M | 34.86M | 11.87M | 6.35M | 31.60M |
| 2024 FY | 73.50M | 42.34M | 9.16M | 6.93M | 31.15M |
| 2025 FY | 86.26M | 42.62M | 4.80M | 8.15M | 43.63M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -11.89M | -555.00K | -12.44M | — | 22.85M |
| 2023 FY | -10.47M | -6.46M | -16.93M | — | -22.03M |
| 2024 FY | -13.62M | -6.27M | -19.90M | — | -2.71M |
| 2025 FY | -14.53M | -5.51M | -20.04M | — | -4.36M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 67.27M | 34.23M | — | — | — |
| 2023 FY | 91.66M | 86.15M | — | — | — |
| 2024 FY | 177.29M | 175.06M | — | — | — |
| 2025 FY | 210.01M | 213.36M | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 5.71M | 1.34M | -5.72M | -13.32M | -1.23 |
| 2025 Q3 | 5.43M | 896.00K | -6.53M | -2.65M | -0.24 |
| 2025 Q4 | 1.87M | 278.00K | -7.81M | -7.18M | -0.56 |
| 2026 Q1 | 1.48M | 323.00K | -7.98M | -2.95M | -0.23 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 67.00M | 46.88M | 1.06M | 8.07M | 20.12M |
| 2025 Q3 | 94.42M | 44.27M | 59.09M | 17.60M | 50.16M |
| 2025 Q4 | 86.26M | 42.62M | 4.80M | 8.15M | 43.63M |
| 2026 Q1 | 79.98M | 38.56M | 44.65M | 8.13M | 41.42M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -5.76M | -1.05M | -6.81M | — | -300.00K |
| 2025 Q3 | -3.24M | -1.05M | -4.28M | — | 31.68M |
| 2025 Q4 | -3.02M | -2.45M | -5.47M | — | -27.94M |
| 2026 Q1 | -6.75M | -1.82M | -8.57M | — | 10.55M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 209.88M | 216.89M | — | — | — |
| 2025 Q3 | 198.62M | 157.13M | — | — | — |
| 2025 Q4 | 236.76M | 240.11M | — | — | — |
| 2026 Q1 | 207.40M | 170.88M | — | — | — |